Stock KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. NewAmsterdam Pharma Company N.V. Börse Stuttgart

Equities

KH6

NL00150012L7

Market Closed - Börse Stuttgart
Other stock markets
 10:14:14 2024-06-28 am EDT 		5-day change 1st Jan Change
17.9 EUR +0.56% Intraday chart for NewAmsterdam Pharma Company N.V. +6.55% +80.81%
Jun. 11 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
Jun. 10 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TD Cowen Starts NewAmsterdam Pharma With Buy Rating
MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target
MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk
MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target
MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target
MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating
MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target
MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target
MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target
MT
William Blair Starts NewAmsterdam Pharma at Outperform
MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. KH6 Stock
  5. News NewAmsterdam Pharma Company N.V.
  6. Analyst Reco.